Featured Research

from universities, journals, and other organizations

Safe, Well-tolerated, And Effective Treatment For Metastatic Esophageal Cancer

Date:
March 5, 2009
Source:
World Journal of Gastroenterology
Summary:
Patients with metastatic esophageal squamous cell cancer face a dismal prognosis, as no effective standard chemotherapy exists. A research group in China investigated the efficacy, toxic reaction and survival period of Oxaliplatin combined with capecitabine in treatment of patients with in patients with metastatic esophageal squamous cell cancer, and assessed the efficacy, toxicity and survival of the combination therapy.

Metastatic esophageal squamous cell cancer has very poor prognosis. Conventional surgery is considered the most effective treatment, but many cases are inoperable at the time of diagnosis.

More recently, chemotherapy has shown activity in metastatic ESCC. However, no generally accepted standard chemotherapy for advanced. In addition, more and more people pay close attention to the research of optimizing chemotherapy regimen.

Oxaliplatin is one kind of chemotherapeutic drug belonged to the third generation of platinum, which has played an important role in the treatment of colon and rectum cancer and other solid tumors. It has the synergistic effect with 5-FU with the slighter digestive tract reaction and hematotoxicity. Capecitabine which has the slighter side effect is the prosoma of 5-FU and can be taken orally and rapidly absorbed as an intact molecule in the gastrointestinal tract.

A research article to be published on February 21, 2009 in the World Journal of Gastroenterology addresses this question. The research team led by Dr. Qin, Professor Gu and Professor Zhao from Department of Medical Oncology, First Affiliated Hospital of Medical School of Xi'an Jiaotong University, evaluated the efficacy toxic reaction and survival period of Oxaliplatin combined with capecitabine in treatment of patients with in patients with metastatic esophageal squamous cell cancer.

In their study, patients with metastatic metastatic ESCC were treated with oxaliplatin 120 mg/m2 intravenously on day 1 and capecitabine 1000 mg/m2 orally twice daily on days 1 to 14 in a 21-day treatment cycle as palliative chemotherapy. Each patient received at least two cycles. The efficacy, side effects and survival were evaluated then. Treatment was continued until unacceptable toxicity or disease progression.

Out of the 64 patients whose response could be evaluated, the partial response was 43.8%, Stable disease (SD) rate was 47.9% (26/ 64), and disease progression (PD) rate was 15.6% (10/ 64). The clinical benefit rate (PR + SD) was 84.4%. The median overall survival was 10.0 months (95% CI 8.3-11.7 months,respectively. It showed an improvement for quality of life after the chemotherapy

"Capecitabine was given orally twice daily on days 1 to 14 in a 21-day treatment cycle" Said Dr. Zhao. "It showed that this treatment can be given on outpatient basis, therefore the economic burden of the patients can be reduced."

The investigators believed that the oxaliplatin combined with capecitabine treatment provides a safe, well-tolerated, and effective treatment for patients with metastatic ESCC.


Story Source:

The above story is based on materials provided by World Journal of Gastroenterology. Note: Materials may be edited for content and length.


Journal Reference:

  1. Qin et al. Combined treatment of oxaliplatin and capecitabine in patients with metastatic esophageal squamous cell cancer. World Journal of Gastroenterology, 2009; 15 (7): 871 DOI: 10.3748/wjg.15.871

Cite This Page:

World Journal of Gastroenterology. "Safe, Well-tolerated, And Effective Treatment For Metastatic Esophageal Cancer." ScienceDaily. ScienceDaily, 5 March 2009. <www.sciencedaily.com/releases/2009/02/090223091759.htm>.
World Journal of Gastroenterology. (2009, March 5). Safe, Well-tolerated, And Effective Treatment For Metastatic Esophageal Cancer. ScienceDaily. Retrieved September 1, 2014 from www.sciencedaily.com/releases/2009/02/090223091759.htm
World Journal of Gastroenterology. "Safe, Well-tolerated, And Effective Treatment For Metastatic Esophageal Cancer." ScienceDaily. www.sciencedaily.com/releases/2009/02/090223091759.htm (accessed September 1, 2014).

Share This




More Health & Medicine News

Monday, September 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Get on Your Bike! London Cycling Popularity Soars Despite Danger

Get on Your Bike! London Cycling Popularity Soars Despite Danger

AFP (Sep. 1, 2014) Wedged between buses, lorries and cars, cycling in London isn't for the faint hearted. Nevertheless the number of people choosing to bike in the British capital has doubled over the past 15 years. Duration: 02:27 Video provided by AFP
Powered by NewsLook.com
We've Got Mites Living In Our Faces And So Do You

We've Got Mites Living In Our Faces And So Do You

Newsy (Aug. 30, 2014) A new study suggests 100 percent of adult humans (those over 18 years of age) have Demodex mites living in their faces. Video provided by Newsy
Powered by NewsLook.com
Liberia Continues Fight Against Ebola

Liberia Continues Fight Against Ebola

AFP (Aug. 30, 2014) Authorities in Liberia try to stem the spread of the Ebola epidemic by raising awareness and setting up sanitation units for people to wash their hands. Duration: 00:41 Video provided by AFP
Powered by NewsLook.com
California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

Reuters - US Online Video (Aug. 30, 2014) California lawmakers pass a bill requiring universities to adopt "affirmative consent" language in their definitions of consensual sex, part of a nationwide drive to curb sexual assault on campuses. Linda So reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins